Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 1011 to 1020 of 1106 total matches.

Drugs for Pneumonia

   
Treatment Guidelines from The Medical Letter • Sep 01, 2003  (Issue 13)
and antivirals) at the lowest adult dosage, according to data from retail pharmacies nationwide provided ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Treat Guidel Med Lett. 2003 Sep;1(13):83-8 |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
the procedure is not recommended. There are no data to support continuation of prophylaxis after wound closure ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
outcomes, but data demonstrating the safety of vaccination during the first trimester are limited.36 ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
to the patient for 28 days’ use, based on data from retail pharmacies nationwide provided by Scott-Levin’s Source ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 |  Show IntroductionHide Introduction

Cholesterol Rethink for High-Risk Patients

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
for 30 days' treatment, according to the most recent data (March 31, 2004) from retail pharmacies ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Med Lett Drugs Ther. 2004 May 10;46(1182):37-9 |  Show IntroductionHide Introduction

Solifenacin and Darifenacin for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
adult dosage, according to the most recent data (January 31, 2005) from retail pharmacies nationwide ...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Med Lett Drugs Ther. 2005 Mar 14;47(1204):23-4 |  Show IntroductionHide Introduction

Ropinirole for Restless Legs Syndrome

   
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005  (Issue 1214)
days’ treatment, according to the most recent data (June 30, 2005) from retail pharmacies nationwide ...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Med Lett Drugs Ther. 2005 Aug 1;47(1214):62-4 |  Show IntroductionHide Introduction

Pioglitazone/Metformin (Actoplus met)

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006  (Issue 1227)
divided 126.00 1. Cost of 30 days’ supply at the highest daily dosage based on most recent data ...
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination (Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin (Glucophage, and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone....
Med Lett Drugs Ther. 2006 Jan 30;48(1227):9-11 |  Show IntroductionHide Introduction

Coenzyme Q10

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
the cardiotoxicity of anthracyclines, but more data are needed. So far it appears to be safe. 1. RA Bonakdar and E ...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Med Lett Drugs Ther. 2006 Feb 27;48(1229):19-20 |  Show IntroductionHide Introduction

Automated External Defibrillators

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
and visible prompts guide the user through the steps of operation. An internal memory records event data ...
Sudden cardiac arrest has a survival rate of about 6% without immediate defibrillation. Automated external defibrillators (AEDs) can be found in many public locations such as shopping malls, office buildings and schools. Some patients may ask their physicians whether they should purchase an AED for personal use. One device has been FDA-approved for sale over the counter (HeartStart Home Defibrillator - Philips). Purchase of all other AEDs for public places or home use requires authorization from a physician.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):71-2 |  Show IntroductionHide Introduction